Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
Posted: January 14, 2024 at 2:35 am
BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported further steps in its previously-announced restructuring. The restructuring is intended to further reduce expenditures and enable greater concentration of company resources on a planned Phase 1 clinical trial for its lead therapeutic candidate, TTX-MC138. The restructuring follows a strategic review of the company’s operations to identify areas in which it could delay or reduce expenditures, including a previously announced reduction in headcount.
Continued here:
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
Posted in Global News Feed
Comments Off on TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
Posted: January 14, 2024 at 2:35 am
DURHAM, N.C., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the issuance on January 11, 2024 of previously disclosed inducement equity awards to Robert (Rob) Claypoole in connection with this appointment as President and Chief Executive Officer, and Principle Executive Officer of the Company.
Read the original:
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
Posted in Global News Feed
Comments Off on Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
Medicenna Announces Appointment of New Auditor
Posted: January 14, 2024 at 2:35 am
TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the appointment of MNP LLP (“MNP” or “Successor Auditor”) as auditor. The board of directors of the Company accepted the resignation of PricewaterhouseCooper LLP (the “Former Auditor”) and appointed MNP as the new auditor until the next annual general meeting of shareholders of the Company.
Go here to see the original:
Medicenna Announces Appointment of New Auditor
Posted in Global News Feed
Comments Off on Medicenna Announces Appointment of New Auditor
Axial Therapeutics to Present at Upcoming Conferences
Posted: January 6, 2024 at 2:37 am
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, PhD, Chief Executive Officer, will participate in the following upcoming conferences:
Posted in Global News Feed
Comments Off on Axial Therapeutics to Present at Upcoming Conferences
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
Posted: January 6, 2024 at 2:37 am
TORONTO and HAIFA, Israel , Jan. 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that it has closed a non-brokered private placement (the “Private Placement”). An aggregate of 7,091,993 units of the Company (each a “Unit”) were issued and sold under the Private Placement at a price of CAD$0.28 per Unit for aggregate proceeds of CAD$1,985,758.04.
Follow this link:
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
Posted in Global News Feed
Comments Off on NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Posted: January 6, 2024 at 2:37 am
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea
Read this article:
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Posted in Global News Feed
Comments Off on Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T…
Posted: January 6, 2024 at 2:37 am
Expect to disclose initial SC262 clinical data in 2024 Expect to disclose initial SC262 clinical data in 2024
Posted in Global News Feed
Comments Off on Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T…
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,…
Posted: January 6, 2024 at 2:37 am
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024.
Originally posted here:
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,...
Posted in Global News Feed
Comments Off on SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,…
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
Posted: January 6, 2024 at 2:37 am
- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively
Read the rest here:
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
Posted in Global News Feed
Comments Off on Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
Posted: January 6, 2024 at 2:37 am
AUSTIN, Texas, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced the completion of a previously announced distribution of warrants (the “Warrants”) to its shareholders. The Warrants now trade on Nasdaq under the ticker SAVAW.
Read this article:
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
Posted in Global News Feed
Comments Off on Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
